Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

81. Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Full Text available with Trip Pro

percentage points; 95% CI, 0.1%-6.8%) and any colorectal cancer screening (18.3% vs 14.5%; difference, 3.8 percentage points; 95% CI, 0.6%-7.0%). We observed large variation across health centers in effectiveness (FIT completion differences range, -7.4 percentage points to 17.6 percentage points) and implementation (proportion who were mailed a FIT range, 6.5% to 68.2%). The number needed to mail to achieve a completed FIT was 4.8 overall, and 4.0 in clinics that mailed a FIT reminder.An EHR-embedded (...) Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Approximately 24 million US individuals receive care at federally qualified health centers, which historically have low rates of colorectal cancer screening. The US Preventive Services Task Force recommends routine colorectal cancer screening for individuals aged 50 to 75 years.To determine the effectiveness of an electronic health record (EHR

2018 EvidenceUpdates

82. Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer Full Text available with Trip Pro

Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer 30225389 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer. 55 10.21037/tgh.2018.07.11 Abdel-Rahman Omar O Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Department of Oncology, University of Calgary, Tom Baker Cancer Centre (...) Cancer. 2013 Sep 15;119(18):3377-84 23801109 Clin Transl Oncol. 2018 Jun;20(6):794-800 29086248 Cancer. 2018 Jul 15;124(14):3008-3015 29797673 J Gastrointest Cancer. 2013 Jun;44(2):203-10 23264206 Gastrointest Cancer Res. 2007 Nov;1(6):248-53 19262903 J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672 29766660 Clin Colorectal Cancer. 2016 Mar;15(1):16-23 26281943 Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72 24078664 J Nutr. 1994 Jun;124(6):906-10 7515956 J Cancer Surviv. 2012 Dec;6(4):398-406 23054848 Dig

2018 Translational gastroenterology and hepatology

83. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment Full Text available with Trip Pro

New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have been applied (...) in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited

2018 Biomedicines

84. Current treatment strategies in pediatric gastrointestinal stromal cell tumor Full Text available with Trip Pro

Current treatment strategies in pediatric gastrointestinal stromal cell tumor Gastrointestinal stromal tumors (GIST) are exceedingly rare tumors in the pediatric population. As a result, many clinicians either may never see this diagnosis or will encounter it only a few times throughout their careers. Additionally, the more we discover about this disease, it becomes evident that it represents a distinct clinical entity from adult GIST. Many of the treatments and strategies used to combat (...) the adult tumor are either ineffective or may be harmful to the pediatric population with this disease. The unique tumor biology found in pediatric GIST necessitates unique approaches and treatment strategies in order to achieve the best clinical outcome. This review aims to discuss the most recent data available on the different therapeutic modalities utilized in cases of Pediatric GIST.

2018 Translational gastroenterology and hepatology

85. Red and processed meat and risk of colorectal cancer: an update Full Text available with Trip Pro

Red and processed meat and risk of colorectal cancer: an update 30190669 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Red and processed meat and risk of colorectal cancer: an update. 792-797 10.17179/excli2018-1554 Benarba Bachir B Laboratory Research on Biological Systems and Geomatics, Faculty of Nature and Life,University of Mascara, Algeria. eng Journal Article 2018 08 08 Germany EXCLI J 101299402 1611-2156 2018 07 22 2018 08 06 2018 9 8 6 0 2018 9 8 6 0 2018 9 8 6 1 epublish 30190669 (...) 10.17179/excli2018-1554 2018-1554 Doc792 PMC6123610 Nutrition. 2018 May;49:17-23 29571606 Eur J Epidemiol. 2017 May;32(5):409-418 28646407 Eur J Cancer. 2018 Feb;90:73-82 29274927 Cancer Epidemiol. 2018 Aug;55:1-7 29753206 J Clin Med. 2018 Jan 30;7(2):null 29385768 Am J Clin Nutr. 2018 Mar 1;107(3):465-479 29566186 Meat Sci. 2014 Aug;97(4):583-96 24769880 PLoS One. 2015 Aug 25;10(8):e0135959 26305323 Clin Nutr. 2017 Jun;36(3):848-852 27206698 Clin Nutr. 2018 Jun;37(3):1019-1026 28526274 Curr Colorectal

2018 EXCLI journal

86. Macrophage repolarisation therapy in colorectal cancer Full Text available with Trip Pro

Macrophage repolarisation therapy in colorectal cancer 30116595 2018 08 17 2059-7029 3 5 2018 ESMO open ESMO Open Macrophage repolarisation therapy in colorectal cancer. e000426 10.1136/esmoopen-2018-000426 Halama Niels N Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, UniversitatsKlinikum Heidelberg, Heidelberg, Germany. eng Journal Article 2018 08 03 England ESMO Open 101690685 2059-7029 Podcast Competing interests: None declared. 2018 8 18 6 0

2018 ESMO open

87. Colon cancer screening

for Disease Control and Prevention (CDC's) Screen for Life materials. Some participants also will be asked to read a personal narrative about colon cancer screening . This study will determine whether participant's perceptions about 2015 16. Colon Capsule to Screen for Colorectal Neoplasia in Subjects with a Family History of Colorectal Cancer . BACKGROUND AND AIMS: Colon capsule endoscopy (CCE) has been recognized as an alternative for colorectal cancer (CRC) screening in average risk subjects (...) administration is a key factor in the tolerability and efficacy of colon preparation in colorectal cancer screening ]. 236-42 10.1016/j.gastrohep.2012.01.012 The quality and tolerability of antegrade (...) gut lavage bowel preparation are key elements in the success of population-based colorectal cancer screening . To evaluate cleansing quality and tolerability according to the timing of polyethylene glycol administration in persons undergoing colorectal cancer screening . Participants in colorectal cancer

2018 Trip Latest and Greatest

88. Colorectal cancer

cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages. OBJECTIVE: To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex 2016 7. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer : a systematic review and economi The clinical effectiveness (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for colorectal cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

89. The Use of CT-Guided Marking for the Laparoscopic Resection of a Solitary Retroperitoneal Metastasis of Colon Cancer Full Text available with Trip Pro

to the tumor by the radiologist. During the surgery, the marker was clearly identified and the cutting line was determined to ensure a sufficient surgical margin. The tumor was laparoscopically resected as planned. The histopathologic diagnosis was adenocarcinoma, compatible with metastasis of colon cancer. The postoperative course was uneventful and the patient remained free of disease at 10 months after surgery. Conclusion: When resecting small tumors or tumors with an irregular margin, a marking (...) The Use of CT-Guided Marking for the Laparoscopic Resection of a Solitary Retroperitoneal Metastasis of Colon Cancer Background: CT-guided marking technique is rarely used in abdominal or urologic surgery. We developed and performed a marking technique for a small tumor, undetectable by ultrasound, using CT guidance before laparoscopic resection of the tumor. Case Presentation: A 73-year-old woman with a history of breast cancer underwent right colectomy with D3 lymph node dissection

2018 Journal of endourology case reports

90. Review gastrointestinal stromal tumors: to prospect the next decade Full Text available with Trip Pro

Review gastrointestinal stromal tumors: to prospect the next decade 30148231 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Review gastrointestinal stromal tumors: to prospect the next decade. 46 10.21037/tgh.2018.07.07 Kanda Tatsuo T Sanjo General Hospital, Niigata, Japan. (Email: kandat@herb.ocn.ne.jp). eng Journal Article 2018 07 23 China Transl Gastroenterol Hepatol 101683450 2415-1289 Conflicts of Interest: The author has no conflicts

2018 Translational gastroenterology and hepatology

91. Colorectal sarcoma: more than a gastrointestinal stromal tumor Full Text available with Trip Pro

Colorectal sarcoma: more than a gastrointestinal stromal tumor Primary colorectal sarcomas have been defined as a rare and diverse group of mesenchymal cancers distinct from gastrointestinal stromal tumors (GISTs). Primary colorectal sarcomas have been recognized as a distinct entity from GISTs due to the dramatically worse prognosis these sarcomas carry. Also, primary colorectal sarcomas when compared to the more common colorectal adenocarcinoma, demonstrate more aggressive biology, present (...) at a younger age and carry worse outcomes. At this time, surgery remains the mainstay of treatment and adjuvant chemotherapy has an unclear role in treatment of primary colorectal sarcoma. This paper attempts to review the available data regarding primary colorectal sarcomas.

2018 Translational gastroenterology and hepatology

92. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer Full Text available with Trip Pro

initially unresectable and previously untreated RAS and BRAF wild-type metastatic colorectal cancer patients are randomised to receive a standard treatment with mFOLFOX6 plus panitumumab or an experimental regimen with modified FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, L-leucovorin 200 mg/m2, 5-fluoruracil 2400 mg/m2 48-hour continuous infusion) plus panitumumab up to 12 cycles, followed by panitumumab plus 5-fluorouracil and L-leucovorin until disease progression. The primary endpoint (...) TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen

2018 ESMO open Controlled trial quality: uncertain

93. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era Full Text available with Trip Pro

Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment.Nationwide population-based data were retrieved from the Netherlands Cancer Registry. All patients with GIST diagnosed between 2001 and 2012 were included. Primary treatment, defined as any treatment (...) compared with 88·8 (86·0 to 91·4) per cent in those with non-metastatic GIST.This population-based nationwide study found an incidence of GIST in the Netherlands of approximately 8 per million person-years. One in five patients presented with metastatic disease, but relative survival improved significantly over time for all patients with GIST in the imatinib era.© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

2018 EvidenceUpdates

94. Bowel Obstruction and Ventral Hernia After Laparoscopic Versus Open Surgery for Rectal Cancer in A Randomized Trial (COLOR II) (Abstract)

Bowel Obstruction and Ventral Hernia After Laparoscopic Versus Open Surgery for Rectal Cancer in A Randomized Trial (COLOR II) The aim of this study was to evaluate the risk of bowel obstruction, incisional, and parastomal hernia following laparoscopic versus open surgery for rectal cancer.Laparoscopic surgery for rectal cancer has been adopted worldwide, after trials reported similar oncological outcomes compared with open surgery. Little is known about long-term morbidity, including bowel (...) in risk of bowel obstruction, incisional, or parastomal hernia following laparoscopic or open surgery for rectal cancer.Based on long-term morbidity outcomes, laparoscopic surgery for rectal cancer could be considered a routine technique as there are no differences with open surgery.

2018 EvidenceUpdates

95. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial (Abstract)

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial Purpose Given the cumulative neurotoxicity associated with oxaliplatin, a shorter duration of adjuvant therapy, if equally efficacious, would be advantageous for patients and health-care systems. Methods The Three or Six Colon Adjuvant trial is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III colon cancer (...) . Conclusion The Three or Six Colon Adjuvant trial failed to formally show noninferiority of 3 versus 6 months of treatment to the predefined margin of 20% relative increase. The results depended on the adjuvant regimen and risk. For CAPOX, 3 months were as good as 6 months; for FOLFOX, 6 months added extra benefit. Counter-intuitively, the low-risk patients benefitted more than the high-risk population from the 6-month duration. The choice of regimen and duration should depend on patient characteristics

2018 EvidenceUpdates

96. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial Full Text available with Trip Pro

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation of Adjuvant (...) Chemotherapy (IDEA) France, as part of the IDEA international collaboration, patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine plus oxaliplatin (CAPOX) by physician choice. The primary end point was disease-free survival (DFS), and analyses were descriptive. Results A total of 2,010 eligible patients received either 3 or 6 months of chemotherapy (modified intention-to-treat

2018 EvidenceUpdates

97. Colorectal cancer

Colorectal cancer Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) . Also read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

98. The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement

Statement R. Goodwin, C. Agbassi, E. Kennedy, J. Biagi, R. Wong, S. Welch, S. Berry, and the Gastrointestinal Disease Site Group Report Date: July 3, 2018 This document describes the CCO- Gastrointestinal Cancer Disease Site Group endorsement of The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement published in 2017 by Abrahao et al. The original publication is available at Current Oncology Vol 24, No 6 (2017) For information (...) , Agbassi C, Kennedy E, Biagi J, Wong R, Welch S, Berry S, and the Gastrointestinal Disease Site Group. The Role of Primary Tumour Location in the selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement. Toronto (ON): Cancer Care Ontario; 2018 May. Program in Evidence-based Care Guideline No.: 2-31. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced

2018 Cancer Care Ontario

99. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options.To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with metastatic CRC.FRESCO (Fruquintinib Efficacy and Safety in 3+ Line (...) Colorectal Cancer Patients) was a randomized, double-blind, placebo-controlled, multicenter (28 hospitals in China), phase 3 clinical trial. From December 2014 to May 2016, screening took place among 519 patients aged 18 to 75 years who had metastatic CRC that progressed after at least 2 lines of chemotherapy but had not received VEGFR inhibitor therapy; 416 met the eligibility criteria and were stratified by prior anti-VEGF therapy and K-ras status. The final date of follow-up was January 17, 2017

2018 JAMA Controlled trial quality: predicted high

100. Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? Full Text available with Trip Pro

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? 29942667 2019 01 30 2059-7029 3 4 2018 ESMO open ESMO Open Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? e000392 10.1136/esmoopen-2018-000392 Roda Desamparados D CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. Ciardiello Fortunato F Oncologia Medica, Dipartimento di Internistica Clinica e (...) Sperimentale 'F. Magrassi', Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. Cervantes Andrés A CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. eng Editorial 2018 06 20 England ESMO Open 101690685 2059-7029 colon cancer Competing interests: None declared. 2018 04 30 2018 05 01 2018 6 27 6 0 2018 6 27 6 0 2018 6 27 6 1 epublish 29942667 10.1136/esmoopen-2018-000392 esmoopen-2018-000392 PMC6012558 Ann Oncol. 2017

2018 ESMO open